ELAB Stock — PMGC Holdings Inc.

PMGC Holdings Inc. (ELAB)

Updated October 16, 2026.

ELAB is a Stock. Its deepest 1-year drawdown was 99.9%.

PMGC Holdings Inc. is a biopharmaceutical company developing aesthetic medicines and therapeutic products, with a lead candidate called EL-22, an engineered probiotic designed to preserve muscle during weight loss treatments. The company also operates segments focused on IT packaging solutions and precision engineering and machining services. The company does not currently have an established distribution schedule.

ELAB performance

Returns are updating. ELAB's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 99.9%.

ELAB key facts

Asset type

Stock

Asset class

Equity

Inception date

11/21/2023

Distribution frequency

None

Last close

$2.77 (as of 2026-10-16)

Market cap

$2,242,534

Average volume

12550.0

Beta

-0.27

Payout ratio

0.0%

EPS

$-1,748.36

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ELAB risks and drawbacks

The deepest 1-year drawdown on record here is 99.9%.

Who may consider ELAB — and who may not

It is a weaker fit for investors who need monthly cash flow (ELAB does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on ELAB

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions